Search research articles
Contact Us
Filters
Showing results (41-50 of 76) with videos related to
Page
of 8
Sort By:
ESMO Open
|
April 13, 2024
Treatment of patients with BRAF<sup>V600E</sup>-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset
M M Germani, G Vetere, F Santamaria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2015
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, et al.
ESMO Open
|
August 20, 2021
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study
A Raimondi, G Fucà, A G Leone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 15, 2023
Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments
J Ros, J Matito, G Villacampa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Toward the molecular dissection of peritoneal pseudomyxoma
F Pietrantonio, F Perrone, A Mennitto, et al.
ESMO Open
|
November 3, 2022
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials
E Dell'Aquila, D Rossini, C A M Fulgenzi, et al.
ESMO Open
|
March 6, 2021
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study
B Borelli, E Fontana, M Giordano, et al.
ESMO Open
|
September 2, 2025
Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients
A Pretta, V Nasca, F Marmorino, et al.
Cytokine & Growth Factor Reviews
|
November 6, 2018
Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting
F De Santis, M Del Vecchio, L Castagnoli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study
C Cremolini, F Morano, R Moretto, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 76) with videos related to
Sort By:
Page
of 8
ESMO Open
|
April 13, 2024
Treatment of patients with BRAF<sup>V600E</sup>-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset
M M Germani, G Vetere, F Santamaria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2015
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, et al.
ESMO Open
|
August 20, 2021
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study
A Raimondi, G Fucà, A G Leone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 15, 2023
Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments
J Ros, J Matito, G Villacampa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Toward the molecular dissection of peritoneal pseudomyxoma
F Pietrantonio, F Perrone, A Mennitto, et al.
ESMO Open
|
November 3, 2022
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials
E Dell'Aquila, D Rossini, C A M Fulgenzi, et al.
ESMO Open
|
March 6, 2021
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study
B Borelli, E Fontana, M Giordano, et al.
ESMO Open
|
September 2, 2025
Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients
A Pretta, V Nasca, F Marmorino, et al.
Cytokine & Growth Factor Reviews
|
November 6, 2018
Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting
F De Santis, M Del Vecchio, L Castagnoli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study
C Cremolini, F Morano, R Moretto, et al.
Page
of 8